Press Release

India Clinical Trials Market to Grow with a CAGR of 8.64% through 2030

Adoption of new technology in clinical research and increasing research & development promoting outsourcing is expected to drive the India Clinical Trials Market growth in the forecast period.

 

According to TechSci Research report, “India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F”, the India Clinical Trials Market stood at USD 2.05 Billion in 2024 and is anticipated to grow with a CAGR of 8.64% through 2030. India Clinical Trials Market is driven by numerous factors, making it an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population provides a broad base for clinical trials, facilitating quicker participant enrolment. The cost-effectiveness of conducting trials in India, due to lower operational and labor costs, attracts global companies.

The presence of a large pool of skilled medical professionals and the increasing government support in streamlining regulations also contribute to the market growth. The growing prevalence of lifestyle diseases in India necessitates the development and testing of new treatment methods, further propelling the clinical trials market.

India Clinical Trials Market, a vital and integral aspect of the healthcare ecosystem, has witnessed remarkable growth and diversification in recent years. This upward trend can be attributed to various factors. India's rich demographic diversity and vast patient pool make it an attractive destination for conducting clinical trials. The cost-effectiveness offered by India further enhances its appeal to global pharmaceutical companies and research organizations. The 2019 amendments to the New Drugs and Clinical Trials (NDCT) Rules have significantly contributed to the market's expansion. These amendments have streamlined the approval processes, introduced compensation provisions, and allowed for concurrent phase I and phase II trials. As a result, companies specializing in therapeutic areas such as oncology, cardiovascular diseases, and diabetes have increasingly chosen India as a preferred location for their clinical trials. This trend aligns with the global prevalence of these diseases and underscores India's potential as a key player in advancing medical research and innovation.

The presence of Contract Research Organizations (CROs) has played a pivotal role in supporting the growth of the clinical trials industry in India. These organizations offer a comprehensive range of services, including site selection, patient recruitment, data management, and statistical analysis. By providing these services, CROs have made the clinical trials process more efficient and manageable for pharmaceutical companies, thereby contributing to the overall development of the market.

It is crucial to address certain challenges in order to sustain and further enhance the growth of the India Clinical Trials Market. Ethical concerns regarding informed consent and patient safety must be given utmost importance. Striking a balance between encouraging clinical trials and ensuring stringent regulations to protect vulnerable patient groups is of paramount significance. Infrastructure and skill deficits in certain regions of the country pose significant hurdles that need to be addressed through strategic investments and capacity building initiatives.

Looking ahead, the India Clinical Trials Market is poised for robust growth. The advent of novel technologies such as virtual and decentralized trials, artificial intelligence (AI), and real-world data has the potential to reshape the landscape of clinical trials in India. The COVID-19 pandemic has highlighted the importance of rapid clinical research and development, setting the stage for a more streamlined and efficient clinical trials market in the future. With deliberate and strategic policies, India can harness this potential and emerge as a global hub for clinical trials, making significant contributions to global healthcare progress and innovation.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "India Clinical Trials Market


India Clinical Trials Market is segmented into phase, study design, indication, regional distribution, and company.

Based on indication, the Oncology sector in India is on the brink of experiencing a substantial surge in the Clinical Trials Market. This growth can be attributed to the alarming rise in cancer prevalence across the country, which has created an urgent need for innovative therapies and breakthrough treatments. The ongoing advancements in cancer research, coupled with the pressing demand for effective clinical trials, are paving the way for significant expansion in the Indian Clinical Trials Market. The expansion of this market not only holds the potential for groundbreaking discoveries but also promises remarkable advancements in the fight against cancer. With the increasing focus on precision medicine and personalized treatments, the demand for clinical trials in India is expected to skyrocket. This presents an opportunity for both domestic and international pharmaceutical companies to collaborate with Indian research institutions and tap into the vast patient population.

The Indian government's initiatives to streamline the regulatory framework and provide incentives for conducting clinical trials have further fueled the growth of this market. The improved regulatory environment coupled with a large pool of experienced healthcare professionals and state-of-the-art infrastructure has positioned India as a preferred destination for conducting oncology clinical trials. The expansion of the Indian Clinical Trials Market not only brings hope to countless individuals and families affected by cancer but also contributes to the overall progress in the field of oncology. It enables researchers to explore novel treatment approaches, validate the efficacy of new drugs, and ultimately improve patient outcomes. The collective efforts of healthcare professionals, researchers, and industry stakeholders in India are driving the advancements in cancer care and shaping a brighter future for oncology patients. The Oncology sector in India is witnessing a surge in the Clinical Trials Market due to the rising cancer prevalence and the need for innovative therapies. This expansion not only presents opportunities for groundbreaking discoveries but also contributes to the fight against cancer, bringing hope and progress to countless individuals and families affected by this devastating disease.

Based on region, western India is currently leading the way in the Clinical Trials Market in India, due to a multitude of contributing factors. One of the key reasons for its dominance is the presence of major pharmaceutical companies and renowned research institutions in the region. This creates a highly conducive environment for conducting clinical trials, fostering a thriving ecosystem that encourages innovation and collaboration. Western India boasts a well-established healthcare infrastructure that supports the seamless execution of various phases of clinical trials. This infrastructure, combined with a large and diverse patient pool, provides ample opportunities for researchers and scientists to carry out comprehensive and robust studies. The availability of such a diverse patient population allows for a better understanding of the effectiveness and safety of new treatments.

The supportive government policies in these states play a crucial role in attracting global pharmaceutical companies to conduct trials in Western India. These policies not only provide incentives but also create a favorable regulatory environment that facilitates the smooth progress of clinical research. As a result, Western India has emerged as a preferred destination for conducting clinical trials, making significant contributions to the advancement of medical science and the development of new therapies. Western India's dominance in the Clinical Trials Market is a result of the region's strong presence of pharmaceutical companies and research institutions, well-established healthcare infrastructure, diverse patient pool, and supportive government policies. These factors collectively contribute to creating an environment that fosters innovation, collaboration, and the successful execution of clinical trials.

 

Major companies operating in India Clinical Trials Market are:

  • IQVIA RDS (India) Private Limited
  • PAREXEL International (India) Private Ltd
  • Icon Clinical Research India Pvt Ltd
  • Veeda Clinical Research Limited
  • Aragen Life Sciences Ltd.
  • Abiogenesis Clinpharm Pvt Ltd
  • Cliantha Research Limited


Download Free Sample Report

Customers can also request for 10% free customization on this report

 

The future trajectory of the clinical trials market in India promises substantial growth, propelled by a convergence of factors that underscore the country's potential as a preferred destination for clinical research endeavors. Foremost among these factors is India's extensive and diverse patient population, presenting a vast reservoir of individuals across different demographics and disease profiles. This diversity not only enhances the inclusivity and generalizability of clinical trial data but also facilitates the evaluation of treatments across varied patient cohorts, offering valuable insights for global drug development programs. India's robust clinical infrastructure, characterized by state-of-the-art medical facilities, specialized research centers, and well-equipped hospitals, positions the country as a conducive environment for conducting clinical trials. Coupled with a cadre of well-qualified investigators and medical professionals adept at adhering to international standards and protocols, India offers a conducive ecosystem for conducting high-quality research studies across therapeutic areas. In addition to its clinical capabilities, India's attractiveness as a clinical trial destination is bolstered by its cost-effectiveness compared to Western counterparts. The relatively lower operational costs, coupled with competitive patient recruitment and retention rates, make India an economically viable option for sponsors and CROs seeking to optimize trial budgets without compromising on quality or efficiency.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

India Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Autoimmune, Blood Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of India Clinical Trials Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India Clinical Trials Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com